Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia

PURPOSE: Pegylated asparaginase is comparatively safer than native asparaginase in the management of acute lymphoblastic leukemia (ALL). However, the high price and nonavailability in low- and middle-income countries limits its use. In 2014, the first generic of pegaspargase (Hamsyl) was approved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nookala Krishnamurthy, Manjunath, Narula, Gaurav, Gandhi, Khushboo, Awase, Ankita, Pandit, Ruta, Raut, Sunil, Singh, Ritu, Gota, Vikram, Banavali, Shripad Dinanath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392740/
https://www.ncbi.nlm.nih.gov/pubmed/32628582
http://dx.doi.org/10.1200/GO.20.00113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392740/
https://www.ncbi.nlm.nih.gov/pubmed/32628582
http://dx.doi.org/10.1200/GO.20.00113

Ejemplares similares